Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa

References

• Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–197.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1–158.
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Bolton-Maggs PHB, Michael Soucie J, et al. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia. 2012;18(3):e91–4.
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Report on the WFH Annual Global Survey 2019. 2020.
   Google Scholar
• White CG, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
   PubMed Web of Science ®Google Scholar
• Australian Haemophilia Centre Directors’ Organisation. Guidelines for the management of haemophilia in Australia. 2016.
   Google Scholar
• National Hemophilia Foundation. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. 2020.
   Google Scholar
• Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2008;14(4):671–684.
   PubMed Web of Science ®Google Scholar
• Davis J, Yan S, Matsushita T, et al. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP. J Med Econ. 2019;22(10):1014–1021.
   PubMed Web of Science ®Google Scholar
• Brennan Y, Parikh S, McRae S, et al. The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors’ Organisation. Haemophilia. 2020;26(3):529–535.
   PubMed Web of Science ®Google Scholar
• Schulte S. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124(Suppl):S6–8.
   PubMed Web of Science ®Google Scholar
• Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102(10):634–644.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): a review of its use in haemophilia B. Drugs. 2017;77(1):97–106.
   PubMed Web of Science ®Google Scholar
• Chia J, Louber J, Glauser I, et al. Half-life– extended recombinant coagulation factor IX–albumin fusion protein is recycled via the FcRn-mediated pathway. J Biol Chem. 2018;293(17):6363–6373.
   PubMed Web of Science ®Google Scholar
• Idelivon, Summary of product characteristics [Internet]. [cited 2021 Apr 21]. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf
   Google Scholar
• Santagostino E. PROLONG-9FP clinical development program-phase i results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res. 2013;131:S7.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405–2411.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761–1769.
   PubMed Web of Science ®Google Scholar
• Kenet G, Chambost H, Male C, et al. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children: results of a phase 3 trial. Thromb Haemost. 2016;116(10):659–668.
   PubMed Web of Science ®Google Scholar
• Iorio A, Blanchette V, Blatny J, et al. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. 2017;15(12):2461–2465.
   PubMed Web of Science ®Google Scholar
• Iorio A, Iserman E, Blanchette V, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017;23(3):e170–e179.
   PubMed Web of Science ®Google Scholar
• Gill JC, Roberts J, Li Y, et al. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. Blackwell Publishing Ltd; 2019. p. e219–e222.
   Google Scholar
• Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065–1074.
   PubMed Web of Science ®Google Scholar
• Kenet G, Chambost H, Male C, et al. Long-Term safety and efficacy of recombinant coagulation factor IX Albumin Fusion Protein (rIX-FP) in Previously treated pediatric patients with hemophilia B: results from a phase 3b extension study. Thromb Haemost. 2020;120(4):599–606.
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323.
   PubMed Web of Science ®Google Scholar
• Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4(2):e75–e82.
   PubMed Web of Science ®Google Scholar
• Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880–3886.
   PubMed Web of Science ®Google Scholar
• Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia. 2016;22(3):381–388.
   PubMed Web of Science ®Google Scholar
• Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13(3):233–243.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Yan S, Maro G, et al. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy. Curr Med Res Opin. 2020;36(1):9–15.
   PubMed Web of Science ®Google Scholar
• Hermans C, Marino R, Lambert C, et al. Real-World utilisation and bleed rates in patients with haemophilia B who switched to recombinant factor IX Fusion Protein (rIX-FP): a retrospective international analysis. Adv Ther. 2020;37:2988–2998.
   PubMed Web of Science ®Google Scholar
• Escobar M, Leissinger C, Yan S, et al. Comparison of rFIX utilization and bleed rates in US hemophilia B patients on rIX- FP and their prior rFIX drug. Presented at: ISTH Congress; 2018 Jul 17–21; Dublin.
   Google Scholar
• Escobar M, Santagostino E, Lessinger C, et al. Prophylaxis with rIX-FP reduces consumption compared with previous FIX in both adult and pediatric patients. Presented at: ISTH Congress; 2017 Jul 8–13; Berlin.
   Google Scholar
• Álvarez-Román M, López M, Martínez M, et al. [Retrospective analysis of the use, effectiveness and quality of life in patients with hemophilia B in prophylaxis treatment with albumin-fused recombinant FIX (rIX-FP) in Spain]. Presented at: XXXVI SETH National Congress; 2020 Oct 26–30; online.
   Google Scholar
• Megías-Vericat J, Rodríguez López M, Poveda J, et al. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa) in Spain. Presented at: ISTH Congress; 2019 Jul 6–10; Melbourne.
   Google Scholar
• Díaz Jordán B, Valverde Templado A, Cebanu T, et al. [Real-life experience using rIX-FP in a patient with hemophilia B on prophylaxis after 100 days of switch to extended life factor IX]. Presented at: XXXVI SETH National Congress; 2020 Oct 26–30; online.
   Google Scholar
• Schiavulli M, Lupone MR, Pollio B, et al. Real-world experience of rIX-FP in two previously untreated paediatric patients with severe haemophilia B in Italy. Presented at: EAHAD Congress; 2021 Feb 3–5; online.
   Google Scholar
• Kleiboer B, Nielsen B, Ma AD, et al. Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: a single centre case series. Haemophilia. 2020;26(1):e23–e25.
   PubMed Web of Science ®Google Scholar
• Malec LM, Croteau SE, Callaghan MU, et al. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US haemophilia treatment centres. Haemophilia. Blackwell Publishing Ltd; 2020. p. e128–e129.
   Google Scholar
• Malec LM, Croteau SE, Callaghan M, et al. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US hemophilia treatment centers. Res Pr Thromb Haemost. 2019;3.
   Google Scholar
• Rampotas A, Desborough MJR, Raza-Burton S, et al. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B. Haemophilia. 2020;26(2):278–281.
   PubMed Web of Science ®Google Scholar
• Herrmann S, Doerr B, May F, et al. Tissue distribution of rIX‐FP after intravenous application to rodents. J Thromb Haemost. 2020;18(12):3194–3202.
   PubMed Web of Science ®Google Scholar
• Herzog E, Harris S, Henson C, et al. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats. Thromb Res. 2014;133(5):900–907.
   PubMed Web of Science ®Google Scholar
• Walsh C, Coppens M, Escobar M, et al. Optimal trough levels in haemophilia B: raising expectations. Haemophilia. Blackwell Publishing Ltd; 2020. p. e334–e336.
   Google Scholar
• Lillicrap D. Evaluating the potential benefits of the extravascular pool of factor IX. Blood Coagul Fibrinolysis. 2021;32(1):68–69.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res. 2013;131:S11–4.
   PubMed Web of Science ®Google Scholar
• Zanon E, Pasca S, Simioni P. The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha. Haemophilia. 2018;24(5):e372–e375.
   PubMed Web of Science ®Google Scholar
• von Mackensen S, Shah J, Seifert W, et al. Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP. Haemophilia. 2019;25(1):45–53.
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Oldenburg J, Boggio L, et al. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: evidence from clinical trials and real-world practice. Haemophilia. 2020;26(4):637–642.
   PubMed Web of Science ®Google Scholar
• Pradelli L, Villa S, Castaman G. Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model. Farmeconomia Heal Econ Ther Pathways. 2018;19:1–10.
   Web of Science ®Google Scholar
• Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308.
   PubMed Web of Science ®Google Scholar
• Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Hematology. 2017;2017(1):595–604.
   PubMed Web of Science ®Google Scholar
• Iorio A, Keepanasseril A, Foster G, et al. Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc. 2016;5(4):e239.
   PubMed Web of Science ®Google Scholar
• Ledger KT, Feussner A, Kalina U, et al. Performance of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in the one-stage assay. Presented at XXXII international congress of the WFH; 2016 Jul 24–26; Orlando.
   Google Scholar
• Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost. 2017;43(3):331–337.
   PubMed Web of Science ®Google Scholar
• Pouplard C, Galinat H, Ternisien C, et al. Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion®). Haemophilia. 2019;25(5):e327–e330.
   PubMed Web of Science ®Google Scholar